Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis

Ajdary, Soheila; Jafari-Shakib, Reza; Riazi-Rad, Farhad; Khamesipour, Ali

doi:10.1016/j.jinf.2006.12.005

Cited by 15 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IL-17 is detected in high levels in subclinical samples as compared to CL samples, suggesting the participation of Th17 in the control of the infection [31]. IL-21R, CD30 (TNRFSF8) and WAS participate of the Th2 polarization during Leishmania infection [32]–[34]. CXCR3 plays a critical role in the host defense against cutaneous leishmaniasis caused by L. major and helps the Th1 response [35], while CCL17 is associated with diffuse leishmaniasis and late LCL cases [35], [36].…”

Section: Discussionmentioning

confidence: 99%

Transcriptome Patterns from Primary Cutaneous Leishmania braziliensis Infections Associate with Eventual Development of Mucosal Disease in Humans

et al. 2012

View full text Add to dashboard Cite

IntroductionLocalized Cutaneous Leishmaniasis (LCL) and Mucosal Leishmaniasis (ML) are two extreme clinical forms of American Tegumentary Leishmaniasis that usually begin as solitary primary cutaneous lesions. Host and parasite factors that influence the progression of LCL to ML are not completely understood. In this manuscript, we compare the gene expression profiles of primary cutaneous lesions from patients who eventually developed ML to those that did not.MethodsUsing RNA-seq, we analyzed both the human and Leishmania transcriptomes in primary cutaneous lesions.ResultsLimited number of reads mapping to Leishmania transcripts were obtained. For human transcripts, compared to ML patients, lesions from LCL patients displayed a general multi-polarization of the adaptive immune response and showed up-regulation of genes involved in chemoattraction of innate immune cells and in antigen presentation. We also identified a potential transcriptional signature in the primary lesions that may predict long-term disease outcome.ConclusionsWe were able to simultaneously sequence both human and Leishmania mRNA transcripts in primary cutaneous leishmaniasis lesions. Our results suggest an intrinsic difference in the immune capacity of LCL and ML patients. The findings correlate the complete cure of L. braziliensis infection with a controlled inflammatory response and a balanced activation of innate and adaptive immunity.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcriptome Patterns from Primary Cutaneous Leishmania braziliensis Infections Associate with Eventual Development of Mucosal Disease in Humans

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Although CL is a self-healing disease but rarely develops to a non-healing form of lesion which does not respond to current available therapies [4][5][6], clinical manifestations of leishmaniasis depend upon the species of Leishmania and the host genetic makeup governs the type of immune response generated [7]. Acquired immune responses in leishmaniasis are extensively studied in animal model and human [8][9][10][11][12][13][14][15], but there are a few studies on the role of innate immune response in leishmaniasis [16][17][18][19]. There are plenty of publications on innate immune response in animal model of leishmaniasis, but only a few studies are completed in human leishmaniasis and still the role of innate immune response in human leishmaniasis is not clear [17,18,20].…”

Section: Introductionmentioning

confidence: 99%

TLR2 and TLR4 in Cutaneous Leishmaniasis Caused by Leishmania major

et al. 2013

View full text Add to dashboard Cite

Cutaneous leishmaniasis (CL) is a self-healing skin disease which rarely for unknown reason(s) the lesion develops to a non-healing form. It seems that the initial contact of Leishmania parasites with the host innate immune system is an important step in the outcome of the disease. Recent studies suggested that tolllike receptors (TLRs) play a role in Leishmania recognition. In this study, the level of TLR2 and TLR4 was checked in patients with healing form of lesion and compared with that of patients with non-healing form of lesion caused by Leishmania major. Gene expression of TLR2 and TLR4 in peripheral bloodderived macrophages, before and after stimulation with live L. major promastigotes, was evaluated using quantitative real-time reverse transcription PCR and flow cytometry. The results showed that the mean relative gene expression and difference membrane expression of TLR2 in macrophages of patients with healing form of lesion were significantly higher than patients with non-healing form of lesion (P < 0.0001 and P = 0.0034), respectively, and the mean relative gene expression and difference in protein expression of TLR4 in macrophages of patients with healing form of lesion were significantly higher than that of patients with non-healing form of lesion (P = 0.021 and P = 0.002), respectively. The data suggested a possible role for TLR2 and TLR4 in the outcome of CL lesion. Further studies are needed to understand more about the detail role of the immune factors in leishmaniasis.

show abstract

“…In addition, other studies have reported that levels of sCD30 have important prognostic value for various lymphoproliferative disorders (4,15,22), systemic lupus erythematosus (SLE) (5,7), and leishmaniasis (1,2). The current method for quantitation of sCD30 is the enzyme-linked immunosorbent assay (ELISA), which has good sensitivity and specificity.…”

mentioning

confidence: 99%

Development and Validation of a Fluorescent Microsphere Immunoassay for Soluble CD30 Testing

Pavlov¹,

Martins²,

Delgado

2009

Clin Vaccine Immunol

View full text Add to dashboard Cite

Testing for soluble CD30 (sCD30), an indicator of Th2 immune response, is a useful prognostic marker in solid organ transplantation, lymphoproliferative disorders, autoimmunity, and various parasitic diseases. In this study we report the development and validation of a fluorescent microsphere immunoassay for the detection of sCD30 in serum, plasma, and culture supernatants. The dynamic range of this assay is 1 to 400 ng/ml, and the rate of recovery of various concentrations of recombinant sCD30 ranges from 97 to 116% (average recovery, 105%). The test showed a high degree of precision in both intra-assay and interassay studies (coefficients of variation, as high as 7% and 8%, respectively), with a sensitivity of 1 ng/ml. The normal reference range calculated for a cohort of 151 healthy individuals was 1 to 29 ng/ml. The clinical usefulness of the sCD30 fluorescent microsphere immunoassay was demonstrated by showing that levels of sCD30 have a positive correlation with specimens containing high titers of anti-double-stranded DNA antibodies and high titers of immunoglobulin G against Leishmania species. Given the multiplexing potential of the sCD30 fluorescent microsphere immunoassay reported in this study, it is expected that testing of sCD30 concentrations along with those of other cytokines will become an important diagnostic tool for selected immunological and inflammatory diseases where Th2-type cytokine responses have been reported. CD30 (TNFRSF 8) is a transmembrane protein, a member of the tumor necrosis factor (TNF) receptor superfamily. It was originally described as a marker for Reed-Sternberg cells ("Ki-1 antigen") in Hodgkin's disease (12,18,20). CD30 is expressed on CD4 ϩ and CD8 ϩ T cells that secrete Th-2 type cytokines (8, 17). Signaling through CD30 plays important roles in T-and B-cell growth, differentiation, and function. The soluble form of CD30 (sCD30) is produced after proteolytic cleavage of the membrane-bound CD30 ectodomain by the TNF-␣-converting enzyme (9).Numerous studies have reported that circulating levels of sCD30 may represent a biomarker for outcomes in solid-organ transplantation (16,21). In addition, other studies have reported that levels of sCD30 have important prognostic value for various lymphoproliferative disorders (4,15,22), systemic lupus erythematosus (SLE) (5, 7), and leishmaniasis (1, 2). The current method for quantitation of sCD30 is the enzyme-linked immunosorbent assay (ELISA), which has good sensitivity and specificity. However sCD30 production differs greatly between patients, and the dynamic range of ELISAs requires that many samples be diluted and retested. Moreover, ELISA measures only 1 analyte per well, which precludes the testing of multiple analytes in the same test. In this study, we report the development and validation of a fluorescent microsphere immunoassay suitable for multiplexed determination of sCD30 levels, along with those of other cytokines, in serum and plasma specimens and in tissue culture supernatants. We present data showing the positiv...

show abstract

Soluble CD26 and CD30 levels in patients with anthroponotic cutaneous leishmaniasis

Cited by 15 publications

References 28 publications

Transcriptome Patterns from Primary Cutaneous Leishmania braziliensis Infections Associate with Eventual Development of Mucosal Disease in Humans

Transcriptome Patterns from Primary Cutaneous Leishmania braziliensis Infections Associate with Eventual Development of Mucosal Disease in Humans

TLR2 and TLR4 in Cutaneous Leishmaniasis Caused by Leishmania major

Development and Validation of a Fluorescent Microsphere Immunoassay for Soluble CD30 Testing

Contact Info

Product

Resources

About